Though the comparability is limited by different study designs, these results are largely consistent with the clinical data observed with other complement inhibitors in CAD, including the intravenously administered monoclonal antibody sutimlimab [13, 14] and the complement C3 inhibitor pegcetacoplan [15], administered via subcutaneous infusion pump. Here, C3 is linked to cold agglutinin disease.